Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 12/20 | 0.52 |
| ▸ | THRB | P10828 | 12/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 10/20 | 0.51 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.51 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | ASPH | Q12797 | 1/20 | 0.51 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522930 | 0.94 | THRA (0.56) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL523958 | 0.89 | EGLN1 (0.59) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL522556 | 0.88 | EGLN1 (0.58) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL521900 | 0.83 | EGLN1 (0.66) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL4758417 | 0.83 | EGLN1 (0.52) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL522660 | 0.83 | EGLN1 (0.59) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL4755914 | 0.80 | EGLN1 (0.65) | THRATHRBEGLN1BBOX1FTO | |
| Acetic Acid SCHEMBL4758815 | 0.79 | THRA (0.48) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL30274512 | 0.79 | EGLN1 (0.66) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL521839 | 0.79 | EGLN1 (0.66) | THRATHRBEGLN1BBOX1FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919463-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2006138511-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2006-12-28 | — | — | WO | disclosed |